BioNTech Has Had a Rough Year. Why It's a Stock Worth Owning.

BioNTech, like all Covid-19 vaccine makers, has gotten crunched in 2023. But it has so much cash that it would have appealed to Warren Buffett’s mentor,...

Related Keywords

Benjamin Graham ,Andrew Bary ,Warren Buffett ,Pfizer ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Vaccines ,Healthcare Life Sciences ,Biopharmaceuticals ,Specialized Drugs Medications ,Political General News ,Health ,Immunizations ,Medical Treatments Procedures ,Synd ,Biotech And Pharma ,Companies ,Healthcare ,Biontech Se ,Bntx ,Biontech ,Political ,General News ,Medical Treatments ,Procedures ,Life Sciences ,Specialized Drugs ,Medications ,